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DNA damage responseHere, we investigated the inﬂuence of Rac family small GTPases on mechanisms of the DNA damage response
(DDR) stimulated by topoisomerase II poisons. To this end, we examined the inﬂuence of the Rac-speciﬁc
small molecule inhibitor EHT1864 on Ser139 phosphorylation of histone H2AX, a widely used marker of the
DDR triggered by DNA double-strand breaks. EHT1864 attenuated the doxorubicin-stimulated DDR in a subset
of cell lines tested, including HepG2 hepatoma cells. EHT1864 reduced the level of DNA strand breaks and in-
creased viability following treatment of HepG2 cells with topo II poisons. Protection by EHT1864 was observed
in both p53wildtype (HepG2) andp53 deﬁcient (Hep3B) human hepatoma cells and, furthermore, remained un-
affected upon pharmacological inhibition of p53 in HepG2. Apparently, the impact of Rac on the DDR is indepen-
dent of p53. Protection fromdoxorubicin-inducedDNA damage by EHT1864 comprises both S andG2phase cells.
The inhibitory effect of EHT1864 on doxorubicin-stimulated DDRwasmimicked by pharmacological inhibition of
various protein kinases, including JNK, ERK, PI3K, PAK and CK1. EHT1864 and protein kinase inhibitors also atten-
uated the formation of the topo II-DNA cleavable complex. Moreover, EHT1864 mitigated the constitutive phos-
phorylation of topoisomerase IIα at positions S1106, S1213 and S1247. Doxorubicin transport, nuclear import/
export of topoisomerase II and Hsp90-related mechanisms are likely not of relevance for doxorubicin-
stimulated DDR impaired by EHT1864. We suggest that multiple kinase-dependent but p53- and heat shock
protein-independent Rac-regulated nuclear mechanisms are required for activation of the DDR following treat-
ment with topo II poisons.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Small GTPases of the Rho (Rho = Ras homologous) family play
pivotal roles in the regulation of a variety of cellular functions, including
proliferation and gene expression as well as regulation of the actin
cytoskeleton and apoptosis [1–3]. Among this family, Rac1 is a key
regulator of genotoxic stress-induced activation of stress-activated
protein kinases/c-Jun-N-terminal kinases and p38 kinases [4,5] and
related transcription factors including NF-kB and AP1 [6,7]. Due to
the pleiotropic functions of Rho GTPases in tumor development and pro-
gression, targeting of Rho functions is suggested as therapeutic strategy
to improve anticancer therapy [8,9]. Rho-regulated mechanisms do not
only promote the anticancer efﬁcacy of conventional anticancer drugs
[10] but also attenuate adverse effects of ionizing radiation and topo-
isomerase II inhibitors on normal tissue [11,12]. Therefore, targeting of
Rho signaling might be a promising strategy to widen the therapeutic
window of anticancer therapeutics. One therapeutic option to target
Rho signaling are HMG-CoA reductase inhibitors (statins), which deplete
the cellular pool of isoprene precursor molecules, which are essentially
required for Rho function [13]. Most of the pleiotropic functions of49 211 8113013.
ights reserved.statins, including inhibition of cell proliferation [14], induction of cell
death [15], antimetastatic effects [16], increase in the therapeutic efﬁcacy
of a variety of conventional anticancer drugs [17,18] and protection from
anticancer therapy-induced normal tissue damage [11,12] have been
attributed to interference with RhoA and Rac1 [19,20].
Inhibition of topoisomerase II (topo II) by anticancer drugs such as the
anthracycline derivative doxorubicin and the podophyllotoxin etoposide
results in the formation of DNA double-strand breaks (DSBs) [21,22].
DSBs are potent activators of the DNA damage response (DDR) and
trigger cell death [23–25]. Phosphorylation of histone H2AX on S139
(γH2AX) is a well accepted surrogate marker of the DDR induced by
DSBs [22,24,26]. The clinical use of topo II poisons is limited by adverse
effects, in particular cardiotoxicity in case of doxorubicin [27,28], hemato-
logic toxicity in case of etoposide [29] and, for both of them, secondary
leukemia [29,30]. Regarding anthracyclines, redox cycling leading to oxi-
dative stress and the inhibition of type II topoisomerases (i.e. topo IIα and
topo IIβ) are controversially discussed as critical events responsible for
their cardiotoxicity [28,31]. Recently it was shown that mice lacking car-
diac expression of topo II beta are protected from doxorubicin-induced
cardiac injury [32], indicating that inhibition of this topo II isoform by
doxorubicin is most relevant for cardiotoxicity. Regarding Rac1, it was
suggested that this GTPase mediates doxorubicin-induced cardiotoxicity
through both ROS dependent and independent pathways [33]. Targeting
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[10,13,20], has multiple inhibitory effects on stress responses following
exposure of normal cells to anticancer therapeutics. For instance, statins
inhibit the activation of the DDR of human endothelial cells (HUVEC)
and smooth muscle cells stimulated by ionizing radiation [34,35] and,
moreover, attenuate doxorubicin- and etoposide-induced stimulation of
the DDR inHUVEC and rat cardiomyoblasts (H9c2) in vitro [34,36,37]. Be-
sides, beneﬁcial effects of statin-mediated inhibition of Rho-signaling on
normal tissue damage provoked by anthracyclines and ionizing radiation
have been reported [38,39]. Recently, binding of Rac1 to topoisomerases
has been demonstrated [40], suggesting that Rac1 might have an addi-
tional nuclear function, which is related to topoisomerases. In the present
study we investigated the inﬂuence of Rac-regulated mechanisms on
the complex network of DNA damage-triggered stress responses evoked
by the topoisomerase II poisons doxorubicin and etoposide. To this
end, the Rac-speciﬁc small-molecule inhibitor EHT1864 was employed
[41,42].
2. Materials and methods
2.1. Materials
The following antibodies were used in our study: γH2AX (pS139),
H2AX and Rac1 were from Millipore (Billerica, MA, USA), γH2AX
(pS139), topo IIα (pS1106), GAPDH, lamin B2, Chk2 (pThr68) and Chk2
were obtained from Epitomics (Burlingame, CA, USA). ATM (pS1981),
Histone H3 (pS10), Akt (pS473), Akt, p38 (pThr180/pTyr182), p53
(pS15), NF-κB subunit p65, cleaved caspase-7 and BRCA1 originate
from New England Biolabs (Frankfurt, Germany), survivin, cyclin B1,
ERK2, p38 and JNK (pThr183/pTyr185) were from Santa Cruz (CA,
USA). Topo IIα was provided by Enzo Life Sciences (Lörrach, Germany),
topo IIβ by Abcam (Cambridge, MA, USA), p53 by Exbio Praha (Prague,
Czech Republic), HSP90 by Cayman Chemical Company (MI, USA),
HSP70 by Biosciences Inc. (Allentown, PA, USA), β-Actin and JNK by
Sigma Aldrich (Hamburg, Germany), and Alexa Fluor 488 by Invitrogen
(Paisley, UK). HRP conjugated secondary anti-mouse antibody and HRP
conjugated secondary anti-rabbit antibody were from Rockland Immu-
nochemicals (Gilbertsville, PA, USA).
The inhibitors used were purchased from the following providers and
used at the concentrations indicated: Rac1 small molecule inhibitors
EHT1864 (10 μM) and NSC23766 (100 μM), JNK inhibitor SP60025
(10 μM), PAK inhibitor IPA-3 (10 μM) (Tocris, Bristol, UK), p38 inhibitor
SB203580 (10 μM), ERK inhibitor PD98059 (10 μM) (Merck Millipore,
Darmstadt, Germany), Akt inhibitor 1L6-Hydroxymethyl-chiro-inositol-
2-(R)-2-O-methyl-3-O-octadecyl-sn-glycerocarbonate (5 μM), BCR-Abl
inhibitor II (10 μM), CDK1 inhibitor 3-(2-Chloro-3-indolylmethylene)-
1,3-dihydroindol-2-one (10 μM) (Merck Calbiochem, Darmstadt,
Germany), Hsp90 inhibitor geldanamycin (10 μM), PI3K inhibitor 3MA
(10 μM) (InvivoGen, Toulouse, France), p53 inhibitor piﬁthrin-α
(30 μM), protein kinase CK1 inhibitor IC261 (10 μM and 30 μM), CK2
inhibitor resoruﬁn (30 μM), Scr-family tyrosine kinase inhibitor
PP2 (10 μM), nuclear import inhibitor Ivermectin (25 μM) (Sigma-
Aldrich, Hamburg, Germany), NF-kB inhibitor SC-3060 (10 μM), nuclear
export inhibitor ratjadone C (10 μM) (Santa Cruz, CA, USA), EGF receptor
inhibitor Iressa (10 μM) (AstraZeneca, London, UK). Cell permeable Rac1
inhibitory peptides comprising the amino acid sequence of the Rac1 effec-
tor binding region (Rac1-Switch I domain (AA 24–45)) (10 μM), the
sequence of Rac1 to which GTPase activating protein (GAPs) binds (Rac-
GAPdomain (AA74–90)) (10 μM)or of the CRIB domain of theRac1 effec-
tor p21-associated protein kinase (PAK1) (PAK1-CRIB domain (AA 70–
94)) (10 μM) were synthesized by JPT Peptide technology GmbH
(Berlin, Germany). The peptides contain a C-terminal HIV-TAT in order
to enable uptake (HIV-TAT/Rac-SwitchI (24–45): YGRKKRRQRRR-PP-
NAFPGEYIPTVFDNYSANVM; HIV-TAT/Rac-GAP (74–90): YGRKKRRQRRR-
PP-QTDVFLICFSLVSPASF HIV-TAT/PAK1-CRIP (70–94): YGRKKRRQRRR-
PP-KERPEISLPSDFEHTIHVGFDAVTG). The topo II poisons doxorubicinand etoposide were provided by the pharmaceutical department of
the University Medical Center of the Heinrich Heine University
Düsseldorf.
2.2. Cell culture and drug treatment
Human hepatoma cells (HepG2 and Hep3B), rat hepatoma cells
(H4IIE), human colon carcinoma cells (HCT116 and HT29), human
embryonic kidney cells (HEK293) and rat kidney epithelial cells
(NRK-52E) were grown at 37 °C in DMEM + 10% fetal calf serum,
100 U/ml penicillin and 100 μg/ml streptomycin. Immortalized
human endothelial cells (EA.hy926) were grown at 37 °C in
DMEM + 10% fetal calf serum + HAT supplement (Sigma-Aldrich,
Hamburg, Germany) and the aforementioned antibiotics. Primary
human umbilical vein endothelial cells (HUVEC) were grown at
37 °C in ECGM2 (PromoCell, Heidelberg, Germany) plus antibiotics.
Human DLD1 carcinoma cells and rat kidney endothelial RGE cells
were grown at 37 °C in RPMI supplemented with 10% fetal calf
serum plus antibiotics. Human ovarian cancer cells (A2780) were
cultured at 37 °C in RPMI supplemented with 10% fetal calf serum,
2 mM glutamine and antibiotics. If not stated otherwise, treatment
of logarithmically growing cells with topoisomerase inhibitors was
performed for 4 h. Pre-treatment with Rac-speciﬁc small molecule
inhibitor EHT1864, which causes guanine nucleotide displacement,
prevents nucleotide exchange by guanine exchange factors (GEFs)
and inhibits downstream signaling [41,42], was performed for 1 h.
2.3. Preparation of cell extracts
For preparation of total cell extracts identical number of cells
were lysed in 300 μl Roti®-Load 1 sample buffer (Roth, Karlsruhe,
Germany). After sonication (EpiShear™ (2 mm), Active Motif, Carlsbad,
CA, USA), extract was incubated for 5 min at 95 °C. After centrifugation
(5 min, 14,000 ×g, RT) the supernatant was used for western blot anal-
ysis. For preparation of nuclear and cytosolic extracts, about 2 × 106
cells were lysed in 300 μl buffer containing 10 mM Tris/HCl (pH 7.5),
50 mM NaCl, 0.5 M Sucrose, 0.1 mM EDTA, 0.5% Triton-X 100, 1 mM
DTT, 1 mM PMSF, 1 mM Na3VO4 and a protease inhibitor mix (Roche,
Mannheim, Germany). Extracts were incubated for 5 min on ice before
centrifugation (10 min, 1000 ×g, 4 °C). The supernatant, which con-
tains cytosolic proteins, was centrifugated again (15 min, 14,000 ×g,
4 °C) to remove ﬂoating particles before Roti®-Load1 sample buffer
was added. The pellet was used for isolation of nuclear proteins. To
this end, it was resuspended in buffer (about 4× the volume of the pel-
let) containing 10 mM Tris/HCl (pH 7.5), 500 mM NaCl, 0.2 mM EDTA,
0.1% NP-40, 0.1% tergitol, 1 mM DTT, 1 mM PMSF, 1 mM Na3VO4 and a
protease inhibitor mix. After sonication (5 times for 1 s, ampl. 25%),
samples were incubated for 5 min on ice before Roti-load sample buffer
was added.
2.4. Western blot analysis
Proteins were separated by SDS-PAGE (7.5–15%), transferred onto a
nitrocellulose membrane. After blocking in 5% non-fat milk in TBS/0.1%
Tween for 1 h at RT, incubation with the primary antibody was
performedover night at 4 °C. Afterwashing, incubationwith peroxidase
conjugated secondary antibody (1:2000) was performed for 2 h at RT.
For visualization of the bound antibodies Fusion FX7 imaging system
(Peqlab, Erlangen, Germany) was used.
2.5. Immunoprecipitation experiments
Cells were lysed in 300 μl lysis buffer (25 mM Tris pH 7.5, 150 mM
NaCl, 1 mM EDTA, 1% NP-40, 5% glycerol, 1 mM PMSF, 1 mM Na3VO4,
protease inhibitor mix). After sonication and centrifugation (2 min,
14,000 ×g), 50 μl of the supernatant was taken for input control (done
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the supernatant, followed by incubation for 1–2 h at 4 °C on a rotating
shaker. 100 μl of A/G-Beads (Santa Cruz, CA, USA), whichwere calibrat-
ed in lyses buffer, was added to the cell lysate. After incubation over
night on a rotating shaker at 4 °C, beads were pelleted (1 min,
1000 ×g) and washed 3 times with lysis buffer. Afterwards 1× Roti-
load sample buffer (Roth, Karlsruhe, Germany) was added, followed
by incubation for 15 min at 37 °C (gently shaking) and heating for
5 min 95 °C. After centrifugation, the supernatant was subjected to
western blot analysis.
2.6. Analysis of H2AX phosphorylation by FACS
Quantitative evaluation of the level of Ser139-phosphorylated
H2AX, which is indicative of DNA damage [24], was done either
by western blot analysis or by FACS-based analysis. For FACS-based
quantitation of γH2AX levels, cells (about 2 × 106) were trypsinated,
washed with PBS (300 ×g, 4 min) and resuspended in 0.5 ml PBS.
4.5 ml ice cold 1% methanol free formaldehyde solution was added
and the suspension was incubated on ice for 15 min. After washing
with PBS (300 ×g, 4 min) and resuspending in 0.5 ml PBS, the suspen-
sion was added to 4.5 ml −20 °C cold 70% ethanol and incubated at
−20 °C for at least 2 h. Afterwards, cells were pelleted (200 ×g for
4 min), ethanol was removed, the cell pellet was washed with BSA-
TPBS solution (1% BSA in PBS TritonX-100 0.2% (v/v)), followed by incu-
bation 2 ml BSA-TPBS for 5 min at RT. After centrifugation (300 ×g for
4 min) cells were resuspended in 100 μl BSA-TPBS containing 1 μg
γH2AX antibody and incubated over night at 4 °C. After washing,
100 μl BSA-TPBS containing 1 μg FITC-tagged secondary antibody
(Alexa Fluor 488)was added and incubated for 1 h at RTwith occasion-
ally shaking. After adding 5 ml of BSA-TPBS, incubation for 2 min at RT
and centrifugation (300 ×g for 4 min), cells were resuspended in 1 ml
of PI staining solution (PBS containing 100 mg/ml RNase A (Sigma-
Aldrich, Hamburg, Germany) and 5 μg/ml propidium iodide). After in-
cubation for 1 h at RT in the dark, the cells were analyzed via FACS.
2.7. Analysis of cell viability
Cell viability was analyzed using the water soluble tetrazolium salt
(WST-1) assay according to the manufacturers' protocol (Roche Diag-
nostics, Mannheim, Germany). Brieﬂy, the cell permeable tetrazolium
salt is cleaved by the mitochondrial reductase system that is present
in metabolically active (viable) cells, resulting in the formation of a
formazan dye. Absorbance of this dye can bemeasured photometrically
(max. absorption at 440 nm; reference wavelength 600 nm).
2.8. Analysis of DNA strand break induction (Comet assay)
Formation of DNA strand breaks was assayed by the alkaline comet
assay [43]. Comets were visualized bymicroscopy and quantiﬁed by de-
termination of the percentage of DNA in the tail (Komet 4.02, Kinetics
Imaging, UK). 50 nuclei were evaluated per treatment.
2.9. Doxorubicin import/export analysis
To analyze doxorubicin transport, cells were treated with 1 μM of
the anthracycline for 2 h. Afterwards, cells were trypsinized, washed
with PBS and ﬁxed with ice cold 70% ethanol for at least 1 h at
−20 °C. The inherent doxorubicin autoﬂuorescence was taken as
indication for the amount of doxorubicin that has been taken up into
the cell and was measured via FACS (excitation: 470 nm; emission:
575 nm). To calculate doxorubicin export, doxorubicin treated cells
were post-incubated in doxorubicin free medium for 6 h before the
residual intracellular amount of doxorubicin was determined by FACS.2.10. Mass spectrometry analysis
After drug treatment, topo IIa proteinwas immunoprecipitatedwith
topo IIα speciﬁc antibody as described above. Immunoprecipitated
protein was separated by SDS-PAGE (7.5%) and the gel was stained
with Coomassie Crystal Blue solution. The topo IIα protein band
was cut out of the gel. Identiﬁcation of phosphorylation sites was
done by mass spectrometry-based analysis performed as service
by the Molecular Proteomics Laboratory (Heinrich Heine University
Düsseldorf).
2.10.1. Analysis of topo II-DNA complex formation by the band-
depletion assay
The formation of the topo II-DNA cleavable complex was ana-
lyzed by the band-depletion assay [44]. High dose of etoposide (i.e.
100 μM) is used to trap active topo II protein to the DNA. Only non-
trapped topo II canmigrate into the polyacrylamide gel and is detect-
able by western blot analysis. Correspondingly, a decrease in topo II
protein level as detected by western blot analysis is indicative of
trapped (i.e. DNA bound) topo II enzyme. HepG2 cells were
preincubated with EHT1864 or various protein kinase inhibitors for
2 h followed by treatment with 100 μM etoposide for 60 min.
Cells were lysed with Roti-load sample buffer (Roth, Karlsruhe,
Germany), sonicated and incubated for 5 min at 95 °C. After centri-
fugation (10 min, 14,000 ×g, RT) supernatants were subjected to
western blot analysis (7.5% SDS polyacrylamide gel) using topo IIα
and topo IIβ speciﬁc antibodies as well asα-tubulin and lamin B2 an-
tibodies for protein loading control.
2.11. Statistical analysis
For statistical analysis the Student's T-test or the Mann–Whitney
U-test was applied. p-Values ≤0.05 were considered signiﬁcant and
marked with an asterisk.
3. Results and discussion
3.1. The inﬂuence of Rac-regulated signaling mechanisms on doxorubicin-
induced DDR is cell-type speciﬁc
In previous study we observed that inhibition of Rac signaling by
statins results in an attenuated DDR of non-malignant endothelial
cells (HUVEC) and rat cardiomyoblasts (H9c2) following treatment
with the anthracycline derivative doxorubicin [12,34,37]. Here we
addressed the question of whether the interference of Rac with
mechanisms of the DDR simulated by topoisomerase II poisons is
speciﬁc for non-malignant cells. To this end, we extended our previ-
ous studies by investigating the inﬂuence of the Rac speciﬁc small-
molecule inhibitor EHT1864 [41,42] on doxorubicin-induced DDR
in various hepatoma and colon carcinoma cell lines. EHT1864 was
employed because in preliminary tests it was found to inhibit
mitogen-stimulated activation of Rac1, as measured by GST-PAK-
mediated pull-down of active (i.e. GTP-bound) Rac1 in HepG2 cells,
more efﬁciently than NSC23766 (data not shown), which is another
type of Rac inhibitor [45]. Liver and colon cells were chosen because
these cell types are exposed to the highest concentration of statins
and other Rac-inhibitory drugs after their oral intake. For additional
control, a number of endothelial cell lines and cell lines from differ-
ent origin were included as well. A total of 13 different cell lines
of human and rodent origin were examined. To monitor the effect
of EHT1864 on doxorubicin-induced DNA damage induction and
mechanisms of the DDR, Ser139 phosphorylation of histone H2AX
(γH2AX), which is a generally accepted surrogate marker of the
DDR triggered by DNA double-strand breaks (DSBs) [22,24,26], was
analyzed by western blot analysis. In addition, activation of p53,
which is another hallmark of the DDR important for the regulation
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by use of an antibody speciﬁcally detecting Ser15-phosphorylated p53
protein (pp53).
Out of three hepatoma cell lines analyzed, EHT1864 reduced the
doxorubicin-stimulated increase in γH2AX levels only in the two
human cell lines HepG2 and Hep3B, but not in rat H4IIE cells (Fig. 1A).
Regarding activation of p53, EHT1864 decreased both the level of
Ser15 phosphorylated p53 and the overall protein amount of p53 in
HepG2 cells (Fig. 1A). Both Hep3B and H4IIE harbor mutated p53 and
do not show p53 protein stabilization following doxorubicin exposure
(Fig. 1A). Neither doxorubicin nor EHT1864 altered the expression
levels of topo II isoforms (Fig. 1A). Next we investigated the expression
of heat shock protein Hsp90 because it interacts with topoisomerase IIα
[46], inﬂuences doxorubicin resistance [47] and, moreover, is also re-
ported to interact with Rac1 [48]. Yet, as shown in Fig. 1A, EHT1864
did not change the level of Hsp90 protein and also not of Hsp70,
which was included as control. The amount of Ser10 phosphorylated
histone H3, which is a mitotic marker, decreased after doxorubicin ex-
posure in the human hepatoma cell lines. This decreasewas not rescued
byEHT1864 (Fig. 1A). Regarding colon carcinoma cells, phosphorylation
of H2AX stimulated by doxorubicin treatment was blocked by EHT1864
in DLD1 cells and, to a weaker extent, in HT29 cells (Fig. 1B). However,
the Rac inhibitor did not mitigate the doxorubicin-stimulated increaseFig. 1. Cell type-speciﬁc inhibition of doxorubicin-induced DDR by EHT1864, a small molecul
of different origin were pretreated or not (C = untreated control) with EHT1864 (10 μM) (E)
protein expression of the indicated proteins was analyzed after further incubation period of
lines; B, human colon carcinoma cell lines; C, human (HUVEC, EA.hy926) and rat (RGE) endo
embryonic kidney (HEK293) and rat tubular kidney (NRK-52E) cells.of pp53 in colon cells (Fig. 1B). Regarding endothelial cells, attenuation
of doxorubicin-stimulated increase in γH2AX and p53 by ETH1864 was
detectable in primary human endothelial cells (HUVEC) only, but not in
immortalized EA.hy926 cells or rat glomerular endothelial cells (RGE)
(Fig. 1C). Other subset of human tumor cell lines also failed to respond
to EHT1864, except MCF-7 mammary carcinoma cells (Fig. 1D). Taken
together, the data show that the requirement of Rac signaling for the
DDR, as reﬂected on the level of γH2AX and pp53, is cell-type speciﬁc
and, apart from primary human endothelial cells [34] and rat
cardiomyoblasts [12,37], also pertains to a subset of tumor cell lines, in-
cluding human hepatoma cells. The data obtained with the various cell
lines are summarized in Supplementary Table 1. The inhibitory effect of
EHT1864 on doxorubicin-induced DDR of HepG2 hepatoma cells is not
due to altered doxorubicin transport. FACS-based analysis of the intra-
cellular doxorubicin concentration showed that neither inﬂuxnor efﬂux
of doxorubicin is affected by EHT1864 (Supplementary Fig. S1). Themo-
lecular mechanism underlying the cell-type speciﬁcity of EHT1864 is
unclear. It is conceivable that it is related to the Rac1 protein level
because, with the exception of A2780 cells, cell lines harboring relative-
ly high amount of Rac1 protein did not respond to EHT1864 co-
treatment with an attenuated DDR stimulated by doxorubicin. An asso-
ciation between EHT1864 responsiveness and the constitutive level of
S1106-phosphorylated topo IIαwas not observed.e inhibitor of Rac family GTPases. Logarithmically growing human and murine cell lines
for 1 h. Afterwards, the anthracycline derivative doxorubicin (D) was added (1 μM) and
4 h by western blot analysis. A, human (HepG2, Hep3B) and rat (H4IIE) hepatoma cell
thelial cell lines; D, human ovarian (A2780) and breast carcinoma cells (MCF7), human
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damage induction and cytotoxicity provoked by topoisomerase II poisons
is independent of p53
EHT1864-mediated inhibition of doxorubicin-induced DDR of
HepG2 cells was paralleled by increase in cell viability (Fig. 2A). The
Rac inhibitor reduced the percentage of cells present in the subG1 frac-
tion andmitigated the accumulation of doxorubicin-treatedHepG2 cells
in S-phase of the cell cycle (Supplementary Fig. S2). The cytoprotective
effects of EHT184 also pertained to the epipodophyllotoxin etoposide
(Fig. 2A), which is another type of topoisomerase II poison. In EHT1864
treated cells, the level of γH2AXwas reduced up to 24 h after doxorubi-
cin or etoposide treatment (Fig. 2B). EHT1864 did not block the increase
in γH2AX following exposure to ionizing radiation (Fig. 2B), showing
that the inhibitory effect of EHT1864 on the DDR is agent speciﬁc. Fur-
thermore, EHT1864 attenuated the doxorubicin-induced phosphoryla-
tion of p53 (pp53) as well as of the stress kinases p38 (pp38) and JNK
(pJNK) but not Akt (pAkt) (Fig. 2C). It also caused an increase in the con-
stitutive expression of the anti-apoptotic factor survivin and mitigated
the proteolytic cleavage of caspase 7 as observed 24 h after doxorubicin
treatment (Fig. 2C). In line with the viability and γH2AX data, EHT1864
also reduced the amount of DNA strand breaks following doxorubicin
and etoposide treatment as analyzed by the alkaline comet assay
(Fig. 2D).Fig. 2. EHT1864 protects human hepatoma cells (HepG2) from the geno- and cytotoxic effects o
for 1 h before doxorubicin (Doxo) or etoposide (Eto) was added at different concentrations as in
ative viability of untreated control was set to 100%. Data shown are the mean ± sd from 3 ind
EHT1864 (10 μM) for 1 h, cells were exposed to the topoisomerase II poisons doxorubicin (1 μM
(IR) (10 Gy). Different timepoints (2–24 h) after treatment, theexpression of S139phosphorylat
as protein loading control. C, untreated control. C: Logarithmically growingHepG2 cellswere pret
B. Up to 24 h after doxorubicin treatment, protein expression of a selected subset of factors was a
1 h were exposed to doxorubicin (1 μM) (Doxo) or etoposide (10 μM) (Eto). After incubation p
breaks was analyzed by the alkaline comet assay. Quantitative data shown in the histogram arep53 plays a pivotal role in the DDR by regulating checkpoint activa-
tion, DNA repair and apoptosis [23]. P53 becomes activated in response
to DSBs or stalled replication forks [23] by phosphorylation, which is cat-
alyzed by the PI3-like kinases AMT/ATR, the key regulators of the DDR.
Bearing in mind the major function of p53 in the regulation of genotoxic
stress responses, we wondered whether it interferes with the geno- and
cytoprotective effects evoked by the Rac inhibitor EHT1864. For this
reason, Hep3B cells, which lack p53 [49], were included in our study. In
line with literature [49], p53 protein stabilization following doxorubicin
exposure was not found in Hep3B cells (Fig. 1A). Similar to what we
observed in HepG2 cells, EHT1864 also protected Hep3B cells from the
cytotoxic effects of doxorubicin and etoposide (Fig. 3A), reduced the
increase in γH2AX levels up to 24 h following treatmentwith topo II poi-
sons (Fig. 3B) and diminished DNA strand break formation (Fig. 3C).
Based on these datawe hypothesized that EHT1864-mediated protection
of hepatoma cells from the geno- and cytoprotective effects of topo II poi-
sons is independent of p53. This hypothesiswas supported by theﬁnding
that Rac inhibition in HepG2 cells, which harbor wildtype p53, leads to a
reduction of doxorubicin-stimulated H2AX phosphorylation even in the
presence of the p53 inhibitor piﬁthrin (Fig. 3D). Piﬁthrin pre-treatment
did not affect H2AX phosphorylation on its own (data not shown). Note-
worthy, while EHT1864 and piﬁthrin did not provoke appreciable
cytotoxicity on their own, co-treatment with EHT and piﬁthrin resulted
in a massive reduction of cell viability (Fig. 3E).f topoisomerase II inhibitors. A: Cells were pretreated or not with EHT1864 (10 μM) (EHT)
dicated. Cell viability was analyzed after incubation period of 72 h using theWST assay. Rel-
ependent experiments each performed in triplicate. *p ≤ 0.05. B: After pretreatment with
) (Doxo) or etoposide (10 μM) (Eto). For control, cells were treated with ionizing radiation
edhistoneH2AX(γH2AX)was analyzed bywestern blot. Expression of ERK2wasmonitored
reatedwith EHT1864 (EHT), followed by addition of doxorubicin (Doxo) as described under
nalyzed. C, untreated control. D: Cells that have been pretreated with EHT1864 (10 μM) for
eriods of 6 h and 2 h for doxorubicin and etoposide, respectively, the level of DNA strand
the mean ± sd from 3 independent experiments. *p ≤ 0.05.
Fig. 3. EHT1864 protects p53 deﬁcient human hepatoma cells (Hep3B) from the geno- and cytotoxic effects of topoisomerase II inhibitors. A: Logarithmically growing p53 deﬁcient Hep3B
cells were pretreated with EHT1864 (10 μM) for 1 h before doxorubicin (Doxo) or etoposide (Eto) was added at different concentrations as indicated. Cell viability was analyzed after
incubation period of 72 h using the WST assay. Relative viability of untreated control was set to 100%. Data shown are the mean ± sd from 3 independent experiments each performed
in triplicate. *p ≤ 0.05. B: After pretreatmentwith EHT1864 (10 μM) for 1 h, Hep3B cells were exposed to the topoisomerase II poisons doxorubicin (1 μM) (Doxo) and etoposide (10 μM)
(Eto). For control, cells were treated with ionizing radiation (IR) (10 Gy). Different time points (2–24 h) after treatment, the expression of S139 phosphorylated histone H2AX (γH2AX)
was analyzed bywestern blot. Expression of ERK2wasmonitored as protein loading control. C, untreated control. C: Hep3B cells that have been pretreatedwith EHT1864 (10 μM) for 1 h
were exposed to doxorubicin (1 μM) (Doxo) or etoposide (10 μM) (Eto). After incubation periods of 6 h and 2 h for doxorubicin and etoposide, respectively, the level ofDNA strand breaks
was analyzed by the alkaline comet assay. Quantitative data shown in the histogram are the mean ± sd from 3 independent experiments. *p ≤ 0.05. D, E: Following pretreatment of p53
wildtype HepG2 cells with the p53 inhibitorymolecule piﬁthrin (Pif) (30 μM, 1 h) in the presence or absence of EHT1864 (10 μM), doxorubicin (1 μM)was added. After incubation period
of 2–24 h, cells were harvested for the analysis of H2AX phosphorylation (γH2AX) (D). HepG2 cells were pretreated for 1 h with piﬁthrin (Pif) (30 μM) alone or in combination with
EHT1864 (EHT) (10 μM). Cell viability was analyzed 72 h later. Data shown are the mean ± sd from three independent experiments each performed in triplicate (E). *p ≤ 0.05.
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of EHT1864 is restricted to a particular subpopulation of cells. To this
end cells were scored with regard to the degree of doxorubicin-
induced DNA strand breaks. As shown in Fig. 4A, EHT1864 predomi-
nantly reduced the frequency of cells that have been severely damaged
by the anthracycline, i.e. cells with ≥40% of their DNA being in the tail
(Fig. 4A). FACS-based cell cycle analysis revealed that cells present in S
and G2 phase express the highest level of γH2AX, indicating that they
contain the highest level of DNA damage (Fig. 4B). EHT1864 equally
lowered doxorubicin-induced DNA damage in both S- and G2-phase
cells (Fig. 4B). Taken together, the data show that inhibition of Rac sig-
naling protects cells present in S- or G-phase from severe DNA damage
following doxorubicin treatment.
3.3. Doxorubicin stimulated DDR can be suppressed by different types
of protein kinase inhibitors and is independent of mechanisms of
nuclear import
Next, we addressed the question as to the Rac downstream path-
ways that are required for activation of the DDR following doxorubicin
exposure of HepG2 cells. To this end, a large variety of pharmacological
inhibitors of protein kinases and other signaling molecules were inves-
tigated with respect to their potency to mitigate the doxorubicin-
stimulated increase in γH2AX as EHT1864 does. Apart from EHT1864,
which was included as internal control, a selected subset of 20 different
inhibitors was used. These extensive analyses showed that a severalpharmacological inhibitors were able to mimic the EHT1864 effect, i.e.
to attenuate the doxorubicin-induced increase in γH2AX level by
≥50% (Fig. 5A, B and supplementary Table 2). Apart from NSC23766,
which is another type of Rac inhibitor [45] blocking Rac1 activity
in HepG2 cells as analyzed by GST-PAK pulldown assay (data not
shown), inhibitors of stress-activated protein kinases/c-Jun-N-terminal
kinases (SAPK/JNK), extracellular regulated kinases (ERK), p21-
associated kinases (PAK), phosphoinositide-3-kinase (PI3K) as well as
of EGFR receptor kinase, c-Abl and c-Src avoided the doxorubicin-
stimulated increase in γH2AX (Fig. 5A and B). Moreover, the
proteasome inhibitorMG132 and the nuclear export inhibitor ratjadone
also showed inhibitory effects. By contrast, inhibitors of p38 kinase, Akt
kinase, protein kinase CK2, cyclin dependent kinase 1 (CDK1), heat
shock protein 90 kDa (Hsp90), NF-κB and inhibitor of nuclear import
(ivermectin) were ineffective (Fig. 5A and B). The observation, that var-
ious kinase inhibitors had inhibitory potency indicates that multiple ki-
nases are required for doxorubicin-stimulated DDR. Attenuation of
doxorubicin-induced increase in γH2AX level by a given inhibitor was
not always paralleled by corresponding reduction of pp53 levels. For in-
stance, inconsistent effects were observed for inhibitors of JNK, CK2,
CDK1, Hsp90 and nuclear import (Fig. 5A and B; Supplementary
Table 2). Apparently, regulatory mechanisms of the DDR involved in
the phosphorylation of H2AX and p53 are not identical.
Inhibition of upstream kinases of Rac, such as the tyrosine kinases
EGFR, c-Abl or c-Src, was less effective in inhibiting doxorubicin-
inducedH2AXphosphorylation as compared to inhibition of downstream
Fig. 4. EHT1864 protects HepG2 cells present in S- and G2-phase from severe DNA damage induced by doxorubicin. A: Logarithmically growing HepG2 cells were pretreated for 1 h with
EHT1864 (10 μM), followed by exposure to doxorubicin (1 μM) for 2 h. For control cells were irradiated (10 Gy) and harvested 15 min after irradiation. DNA strand breaks were analyzed
by the alkaline comet assay as described in theMaterials andmethods. The level of DNA damagewas scored according to the % tail DNA (categories of 10–70%). Data shown are from three
independent experiments with at least 50 nuclei having been analyzed per experiment. B: HepG2 cells were pretreated 10 μM EHT1864 for 1 h, followed by 2 h of doxorubicin (1 μM)
treatment. For control cells were irradiated (10 Gy). After incubation period of 2 h (15 min in case of IR) γH2AX levels were determined by FACS analysis as described in the Materials
and methods. To identify G1-, S- and G2-phase cells, nuclear DNA was co-stained by PI. Mean FL1-H values were determined for cells present in G1-, S- and G2-phase of the cell cycle
and normalized to the IR control (IR value set to 100%). Quantitative data shown are the mean ± sd from four independent experiments performed in triplicate.
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inhibition of ERK is of particular relevance for the attenuation of
doxorubicin-induced DDR by EHT1864, as ERK activates topoisomerase
IIα [50,51] and affects doxorubicin resistance in breast cancer cells [52].
As topoisomerase II cleavable complexes are subject to proteasomal deg-
radation [53], inhibition of the proteasome by MG132 is anticipated to
prevent the degradation of topo II, eventually inhibiting the formation
of DSBs. In line with this assumption, we found that MG132 attenuates
the DDR, as reﬂected by a reduced phosphorylation of H2AX and p53
following doxorubicin treatment (Fig. 5A). Since MG132 stabilized the
formation of the cleavable complex as analyzed by the TARDIS assay,
whereas EHT1864 did not (Supplementary Fig. S3), we suggest that the
inhibitory effect of EHT1864 on doxorubicin-induced DDR does not rest
on an interference with the proteasomal degradation machinery.
Rac1 can translocate to the nucleus via importin α and binds to
topoisomerase II [40]. Also topoisomerase II is imported into the
nucleus by importin α and nuclear export of topoisomerase by CRM1
leads to doxorubicin resistance [54]. Bearing in mind these reports, we
investigated whether the importin inhibitor ivermectin [55] attenuates
doxorubicin-induced DDR to a similar extent as EHT1864 does. We
found that ivermectin further promotes the doxorubicin-stimulated
rise in γH2AX levels (Fig. 5B), rather than causing inhibition as specu-
lated. This ﬁnding indicates that the mechanisms underlying the DDR
inhibitory effect of EHT1864 are independent of alterations in the nucle-
ar import of topoisomerases and Rac. The nuclear export inhibitor
ratjadone partially blocked doxorubicin-stimulated DDR (Fig. 5B).
Protein kinase CK2 phosphorylates topo IIα at several sites and was
shown to affect drug resistance [56]. Based on this report we includedthe CK2 inhibitor resoruﬁn [57] in our studies. Yet, resoruﬁn did not
mimic the inhibitory effect of EHT1864 on doxorubicin-induced DDR.
Rather, it largely increased the level of γH2AX protein (Fig. 5A). Taken
together, the results of the extensive inhibitor studies indicate that
blockage of MAPK, rather than mechanisms of transport, contributes
to inhibition of doxorubicin-stimulated DDR by EHT1864. It should be
noted that inhibition of doxorubicin induced phosphorylation of H2AX
and p53 by EHT1864, JNK inhibitor and MG132 was accompanied by
attenuated autophosphorylation of ATM (Fig. 5C). The phosphorylation
level of checkpoint kinase 2 (Chk2) was not affected by doxorubicin
(Fig. 5C), showing the selectivity of doxorubicin-induced DNA damage
responses.
3.4. Rac1 signaling modulates the phosphorylation status of topoisomerase
IIα
Based on the aforementioned results, we hypothesized that
topoisomerase II is phosphorylated by Rac-regulated protein kinases,
resulting in conformational changes of topoisomerase II, which affects
its interaction with topo II poisons. To substantiate this hypothesis,
we investigated the effect of EHT1864 and the SAPK/JNK inhibitor
SP60025, which showed a profound inhibition of doxorubicin-
stimulated increase in γH2AX levels (see Fig. 5A), on the phosphoryla-
tion status of topoisomerase IIα using an antibody detecting S1106
phosphorylated protein. These analyses were performed in cytosolic
and nuclear extracts of doxorubicin-treated cells and corresponding
non-treated controls. EHT1864 caused a decrease in the level of S1106
phosphorylated nuclear topo IIα enzyme, which was accompanied by
Fig. 5. A subset of protein kinase inhibitors mimic the inhibitory effect of EHT1864 on doxorubicin-induced DDR. A–B: Logarithmically growing HepG2 cells were pretreated for 1 h with
different types of inhibitors, which are described in the Materials and methods. 4 h after addition of doxorubicin (1 μM), the expression level of the indicated proteins was analyzed by
western blot. For densitometrical analysis, the relative amount of γH2AX in the doxorubicin treated cells was set to 1.0. Quantitative data are themean from 2 independent experiments.
C: Logarithmically growing HepG2 cells were pretreated for 1 h with EHT1864 (EHT), JNK inhibitor (JNKi) or proteasomal inhibitor (MG132) as described in the Materials and methods.
4 h after addition of doxorubicin (1 μM), phosphorylation status of key factors of the DDR, i.e. ATM, Chk2, p53 and H2AX was analyzed by western blot.
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ment did not affect the S1106 phosphorylation level of topo IIα. JNK
inhibitor, which reduced the level of p-Jun as expected, had only mar-
ginal inﬂuence on the amount of p-Topo IIα protein (Fig. 6A). Following
doxorubicin treatment, the level of nuclear Rac1 increased, which
again was blocked by EHT1864 and the JNK inhibitor (Fig. 6A). TakenFig. 6. EHT1864 treatment results in a reduced S1106phosphorylation of topoisomerase IIα and
or notwith EHT1864 (10 μM) (EHT) or the JNK inhibitor SP60025 (10 μM) (JNKi) for 1 h. Afterw
cytosolic and nuclear fractions as described in theMaterials andmethods. The expression of sele
of cytosolic and nuclear extracts was checked by analyzing the expression of GAPDH and lam
pretreated with the CK1 inhibitor IC261 (10 μM or 30 μM) for 1 h. Afterwards, doxorubicin (1
dicated antibodies. C: Two hours after treatment of HepG2 cells with doxorubicin (1 μM) topoi
tected as described in the Materials and methods. The frequency of corresponding phosp
unphosphorylated sites. The amino acid sequence containing the consensus sequence (CS)
EHT1864 (10 μM, 1 h).together, the data indicate that nuclear function of Rac1 is involved in
regulating S1106 phosphorylation of topo IIα.
Phosphorylation of topo II at S1106 is reported to be catalyzed bydif-
ferent types of protein kinases, in particular protein kinase CK1 [44] and
protein kinase CK2 [56]. As CK2 inhibition failed to block activation of
the DDR following doxorubicin exposure (see Fig. 5A), we hypothesizeda reduced nuclear import of Rac1. A: Logarithmically growingHepG2 cellswere pretreated
ards, doxorubicin (1 μM)was added for 4 h before cells were harvested for preparation of
cted proteins present in either the cytosol or nucleus was analyzed bywestern blot. Purity
in B2, respectively. B: Logarithmically growing HepG2 cells were left untreated or were
μM) was added for 4 h before cells were harvested for western blot analysis using the in-
somerase IIα protein was immunoprecipitated and phosphorylated amino acids were de-
ho-sites (S1213, S1247 and S1377) was calculated with respect to the corresponding
for particular protein kinases (CDK1, ERK1/2, CK2) is shown. EHT, pretreatment with
Fig. 7. Effect of EHT1864 and various protein kinase inhibitors on topo II-DNA complex
formation as analyzed by the band-depletion assay. Logarithmically growing HepG2
cells were preincubated for 1 h with different types of inhibitors, which are described in
the Materials and methods. Afterwards, cells were treated with a high dose of the topo II
poison etoposide (100 μM). After incubation period of 1 h the protein level of the indicated
proteins was investigated by western blot analysis. Decrease in the level of topo II proteins
(=band-depletion) is indicative of the formation of the topo II-DNA cleavable complex. For
quantitative densitometrical analysis, the relative topo IIαprotein level in untreated control
cells was set to 1.0. The ﬁlter was reprobed with α-tubulin and lamin B speciﬁc antibodies
for protein loading control.
Fig. 8. Effect of EHT on Hsp90–topo IIα interaction. A: HepG2 cells pretreated or not wit
EHT1864 (10 μM) (EHT) for 1 h were exposed to 1 μM doxorubicin (Doxo) for 2 h. After-
wards, immunoprecipitation (IP) was performed with anti-Rac1 and anti-topo IIα anti-
body. Co-immunoprecipitated proteins (Hsp90 and topo IIα) were detected by western
blot analysis as described in the Materials and methods. The lower part of the ﬁgure
shows that identical amount of protein was used for IP experiments (input for IP).
B:HepG2 cellswere treatedwith EHT1864 anddoxorubicin as describedunderA. In addition,
cellswere co-treatedor notwith theHsp90 inhibitor geldanamycinbefore doxorubicin expo-
sure. S139 phosphorylation of H2AX was analyzed by western blot. Relative amount of
γH2AX was set to 1.0 in untreated control (Con).
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inhibitor IC261 in our study. The data obtained show that inhibition of
CK1 blocked the doxorubicin-induced increase in γH2AX and pp53
levels and reduced the amount of S1106 phosphorylated topo IIα to a
similar extent as EHT1864 (Fig. 6B). This ﬁnding indicates that CK1 is
part of the Rac-regulated DDR stimulated by topo II poisons. In exten-
sion of the data obtained by use of S1106-phosphospeciﬁc topo IIα
antibody, we immunoprecipitated topo IIα from untreated and treated
cells and subjected the precipitate to mass spectrometrical analysis in
order to identify additional phosphorylation sites affected by doxorubi-
cin and/or EHT1864. A topo IIα peptide containing the S1106 phosphor-
ylation was not detected. This might be due to the technical limitations
of mass spectrometry. We also cannot rule out the possibility that the
abundance of various phosphopeptides in the immunoprecipitate is
inﬂuenced by selective depletion process resulting from covalent
binding of topo IIα to DNA or enrichment mechanisms resulting from
immunoprecipitation. Nevertheless, we found that treatment with
both doxorubicin and EHT1864 reduced the basal phosphorylation of
topo IIα at position S1213, whereas phosphorylation of S1377 remained
unchanged (Fig. 6C). S1247 phosphorylation was slightly increased
following doxorubicin exposure. Notably, EHT1864 mitigated both
basal and doxorubicin-stimulated S1247 phosphorylation (Fig. 6C).
Both S1213 and S1247 are present within a consensus sequence for
MAPK kinases and CDK1, while S1377 is within a consensus sequence
of CK2. Whereas S1106 phosphorylation of topo IIα has been related
to a reduced cleavable complex formation [44], S1213 and S1247
phospho-sites have been associated with the regulation of G2/M-phase
[58].
Deduced from the mass spectrometry-based data together with the
western blot-based results obtained with the kinase inhibitors, we
suggest that Rac-dependent MAPK-mediated phosphorylation of topo
IIα at S1213 and S1247 as well as CK1-catalyzed phosphorylation of
S1106 are of particular relevance for the interaction of topo II with its
poisons. While the interplay of Rac with stress kinases is well known
[4,5], it is not fully clear how Rac1 and CK1 can interact in the context
of doxorubicin-induced DDR. Noteworthy, it has been shown that CK1
prevents activation of Rac, thereby facilitating non-canonical Wnt
signaling pathways [59,60].
As the inhibitory effect of EHT1864 on doxorubicin-induced DDR
likely rests on a reduced formation of the topo II-DNA cleavable com-
plex [37], we investigated the inﬂuence of the various protein kinase in-
hibitors on the cleavable complex formation using the band-depletion
assay [44]. Etoposide largely stimulates the covalent binding of topo II
to the DNA, which is reﬂected by a large decrease in topo II protein
level detectable by western blot analysis (Fig. 7). EHT1864 partially
prevented the decrease in topo IIα levels (Fig. 7), indicating that Rac in-
hibition disables the formation of the cleavable complex. Bearing in
mind that a very high dose of etoposide is used in the band-depletion
assay, complete protection by EHT1864 cannot be expected. Apart
from EHT1864, inhibition of a subset of protein kinases such JNK, ERK
PI3K aswell as CK1 also partially reduced the formation of the cleavable
complex following etoposide treatment (Fig. 7). These results are in line
with the hypothesis that Rac-regulated protein kinases, in particular
MAPK and CK1, have a permissive role in the DDR evoked by topo II
poisons.
3.5. EHT1864 rescues doxorubicin-induced inhibition of Hsp90–topo
IIα interaction
Apart from Rac-regulated phosphorylation of topoisomerase II addi-
tional mechanisms might contribute to the observed genoprotective
effect of EHT1864. Interaction of Hsp90 and topo IIαwas reported to af-
fect doxorubicin resistance [47,61]. As we did not ﬁnd alterations in the
expression level of topo IIα and Hsp90 protein in response to doxorubi-
cin or EHT1864 treatment (see Fig. 1), we hypothesized that posttrans-
lational mechanismsmay regulate interactions between these proteins.In order to address this question, co-immunoprecipitation experiments
were performed. We observed that Hsp90 co-precipitates with Rac1
and that Rac1–Hsp90 interaction is reduced by both EHT1864 anddoxo-
rubicin treatment (Fig. 8A). Hsp90 also co-precipitates with topo IIα
and Hsp90–topo IIα interaction is blocked by doxorubicin (Fig. 8B).
This effect of doxorubicin is rescued by ETH1864 (Fig. 8B), indicating
that Rac inhibition stabilizes the interaction between topo IIα and
Hsp90. Hsp90 is also known to inhibit the SAPK/JNK regulatory kinase
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phosphorylation of H2AX (see Fig. 5A), we explored the inﬂuence of
the Hsp90 inhibitor geldanamycin on S139 phosphorylation of H2AX
following doxorubicin treatment. Inhibition of Hsp90 by geldanamycin
did not have major effects on the level of γH2AX following treatment
with doxorubicin with or without EHT1864 co-treatment (Fig. 8C).
Taken together, the ﬁndings indicate that binding of Hsp90 to topo
IIα, which causes sequestration of topo IIα, is not of major relevance
for the inhibitory effect of EHT1864 on doxorubicin-stimulated DDR.
Taken together, the data show that pharmacological inhibition of
Rac signaling blocks the DDR induced by topo II poisons in a cell type-
speciﬁc manner. Attenuation of the topo II poison-stimulated DDR
under situation of Rac inhibition is independent of p53, Hsp90–topo II
interaction and the nuclear export/import of topo II. Modiﬁcation of
topo IIα by phosphorylation is known to be important for its stability,
nuclear localization, decatenation activity and DNA binding activity.
Based on our data we suggest that a nuclear function of Rac is required
for phosphorylation of topo II, which in turn is a prerequisite for the
activation of the DDR by topo II poisons. We hypothesize that inhibition
of Rac signaling by EHT1864 disables the phosphorylation of topo IIα
at S1106, S1213 and S1247, which are catalyzed by multiple protein
kinases, including MAPK and CK1. Lack of these phospho-sites results
in structural alterations of the topo II protein that hampers the interac-
tion with its poisons. In consequence, the formation of the topo II-DNA
complex is impeded, which in turn attenuates the formation of DSBs
and, ultimately, the activation of the DDR.
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